NovoCure Ltd. (NVCR)
Novocure: A Mispriced Cash-Generating Biotech With Upside Potential
NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption accelerating, especially for new launches like Optune Pax. Valuation multiples are below sector medians (EV/Sales 2.05x vs. 3.66x), while the pipeline and upcoming Optune Mya launch offer significant upside.
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects
Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
NovoCure: Why I'm Fading The Q2 Earnings Rally
NovoCure remains a Hold as recent gains and operational improvements do not alter its long-term, glioblastoma-centric outlook. Q2 revenue grew 16% Y/Y to $183.6M, with adjusted EBITDA guidance raised to $0–$15M, yet true cash generation remains elusive. Optune Pax's early uptake is promising but too preliminary to signal sustainable growth; its Q2 contribution was just $1.6M.
NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago.
NovoCure Q2 Earnings Call Highlights
NovoCure NASDAQ: NVCR reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it raised full-year revenue and adjusted EBITDA guidance.
